Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00082628
Other study ID # 24380
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date May 28, 2004
Est. completion date September 28, 2005

Study information

Verified date September 2017
Source EMD Serono
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the study is to determine if Serostim® 4 mg administered daily for 12 weeks as treatment for the abnormal fat accumulation and distribution associated with HIV-associated Adipose Redistribution Syndrome (HARS) reduces Visceral Adipose Tissue (VAT, measured by CT scan) more effectively than placebo.


Recruitment information / eligibility

Status Completed
Enrollment 326
Est. completion date September 28, 2005
Est. primary completion date September 28, 2005
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

1. Have written laboratory documentation of an HIV infection by one of the following methods:

- Detectable viral load measured by polymerase chain reaction (PCR) amplification, branched chain DNA (bDNA) signal amplification or the presence of p24 antigen.

- Presence of HIV antibodies confirmed by either Western blot or immunofluorescence assay.

Written laboratory documentation of an HIV infection must be obtained prior to randomization. In the absence of documented historical confirmation, an assay of HIV antibodies will be included in the Screening Laboratory Panel. Results will be confirmed with a Western Blot.

2. Have evidence of excess abdominal adipose deposition when measured by the anthropometric methodology, using the following cut off values:

- Men: Waist circumference >88.2 cm AND waist: hip ratio >= 0.95.

- Women: Waist circumference >75.3 cm AND waist: hip ratio >= 0.9.

3. Are taking antiretroviral medication(s) which is (are) approved or is (are) available under a Treatment IND. The regimen must have remained stable for 30 days prior to study entry. Subjects must also agree not to discontinue or to change their regimen for the duration of the study except as judged medically necessary.

4. Have parameter values less than the following limits (using results from the central laboratory):

- AST, ALT, and amylase <= 3 times the upper limit of normal (Screening).

- Fasting triglycerides <= 1,000 mg/dL (Screening).

- Fasting glucose <110 mg/dL (Screening).

- Two-hour (120 minute) glucose <140 mg/dL (Screening).

5. Weight >= 36 kg (79.3 lb)

6. Be between 18 and 60 years of age (inclusive) unless local law dictates different limits.

7. Sufficiently literate in English to be able to comprehend and complete the Quality of Life Questionnaire.

8. Willing and able to comply with the protocol for the duration of the study.

9. Have voluntarily provided written informed consent (with subject authorization under HIPAA), prior to performing any study-related procedure that is not part of normal medical care, and with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.

10. Female subjects must:

1. Be post menopausal (>= 1 year) or surgically sterilized (i.e., have undergone tubal ligation or hysterectomy)

or

2. Use a contraceptive method for the duration of the study such as:

- Hormonal contraceptive

- Intra uterine device

- Diaphragm with spermicide, or condom with spermicide.

And

3. Must be neither pregnant nor breast feeding.

4. Confirmation that female subjects of childbearing potential are not pregnant must be established by a negative beta-hCG serum pregnancy test during the 14-day screening period prior to Study Day 1. If the beta-hCG serum pregnancy test is performed more than 7 days prior to Study Day 1, a urine pregnancy test must be performed by the site laboratory on Study Day 1 to confirm a negative test result.

Exclusion Criteria:

1. Have an active AIDS-defining opportunistic complication (OC) as defined by the CDC or have had an untreated or suspected serious systemic infection, or have had a persistent fever >= 101°F (38.3°C) during the 30 days prior to study entry.

2. Any active or past history of malignancy, except for localized cutaneous Kaposi's sarcoma (fewer than 10 lesions, none of which are larger than 2 cm, and not on active therapy). Such exceptions must be confirmed in writing by the Serono Study Director.

3. Have a CNS mass or active CNS process associated with neurological findings.

4. Have unstable or untreated hypertension, defined as >= 140/90 mm Hg at the time of the Screening Visit, and/or have initiated or changed antihypertensive therapy in the 30 days prior to Study Day 1.

5. Have an acute critical illness treated in an intensive care unit, e.g., due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure.

6. Have a recent history of sleep apnea or intermittent upper respiratory obstruction.

7. Have any condition, which interferes with informed consent or protocol compliance including, but not limited to, active substance abuse and/or dementia.

8. Are unable to comply with the Concomitant Therapy restrictions including:

- therapy for obesity including therapy with anorexigenic or fat reducing drugs

- anti-diabetic or insulin sensitizing medications

- systemic glucocorticoids

- systemic chemotherapy, interferon or radiation therapy treatment

- androgenic agents including, but not limited to testosterone, nandrolone, oxandrolone, oxymetholone, etc. (testosterone replacement therapy for hypogonadism is the exception to this exclusion and will be allowed if started > 30 days prior to Study Day 1)

- progestational agents, unless used for oral contraception or post-menopausal hormone replacement therapy

- appetite stimulants

- investigational agents, unless approved in advance by the study medical director. Specifically, experimental antiretroviral agents are disallowed, unless available under a treatment IND or expanded access program (30 days).

- Liposuction or other elective plastic surgery

- AIDS wasting therapy or prior growth hormone treatment other than study drug (for 12 months prior to the screening visit)

9. Have ever been diagnosed with any of the following conditions:

- Pancreatitis

- Carpal tunnel syndrome (unless resolved by surgical release)

- Diabetes mellitus

- Angina pectoris

- Coronary artery disease

- Any disorder associated with moderate to severe edema (e.g., ascites, nephrotic syndrome, congestive heart failure, lymphedema).

10. Allergy or hypersensitivity to growth hormone.

11. Are participating in any other clinical studies.

In order to participate in this trial a subject must meet all of the inclusion and exclusion criteria specified above. Requests for protocol exceptions/exemptions must come from a participating, fully initiated site at which a prospective patient has consented to undergo screening. Exceptions/exemptions are only allowed by the Trial Director. There is no program in place to allow drug for a single patient IND, or for an expanded access protocol. This statement holds true for both children and adults.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Placebo matched to serostim® as subcutaneous injection.
Serostim® 4 mg
Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
Serostim® 2 mg
Serostim® 2 mg as subcutaneous injection on alternate days.

Locations

Country Name City State
Canada AIDS Research Program Vancouver British Columbia
United States Albany Medical College Albany New York
United States IDP Research Annandale Virginia
United States AIDS Research Consortium of Atlanta Atlanta Georgia
United States Central Texas Clincial research Austin Texas
United States University of Alabama/Birmingham Birmingham Alabama
United States Community Research Initiative of New England Boston Massachusetts
United States Tufts University School of Medicine Boston Massachusetts
United States Rush University Medical Center Chicago Illinois
United States University of Colorado Health Sciences Center Denver Colorado
United States Office Of Dr Gary Richmond Fort Lauderdale Florida
United States Indiana University Infectious Disease Research Clinic Indianapolis Indiana
United States CARE CLINIC - UCLA Medical Center Los Angeles California
United States 3661 South Miami Avenue Miami Florida
United States Care Resources Miami Florida
United States Hennepin County Medical Center Minneapolis Minnesota
United States St. Luke's Roosevelt Hospital New York New York
United States Weill Medical College of Cornell Universtiy New York New York
United States 1401 N. Palm Canyon Palm Springs California
United States Trials Unit Div of Infectious and Immunologic Diseases Sacramento California
United States UCSD - AntiViral Research Center San Diego California
United States Kaiser Permanente San Francisco California
United States Northern California Institute for Research and Education, Inc. San Francisco California
United States University of California, San Francisco - Div. of Endocrinology San Francisco California
United States Infectious Disease Associates Sarasota Florida
United States Office of Daniel Coulston, M.D. Spokane Washington
United States Community Research Initiative Of New England Springfield Massachusetts
United States Bronx Women's Interagency HIV Study The Bronx New York
United States Harbor-UCLA Medical Ctr Research & Education Institute Torrance California
United States 1640 Rhode Island Avenue, N.W. Washington, D.C. District of Columbia
United States AIDS Alliance West Hollywood California

Sponsors (1)

Lead Sponsor Collaborator
EMD Serono

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12 Absolute area of VAT was measured by cross-sectional computed tomography (CT) scan at the level of the L4-5 inter-vertebral disk. CT scanning was to be used to assess the cross sectional area of abdominal fat and its distribution between the visceral and subcutaneous compartments, as measured at L4-L5. Baseline, Week 12
Secondary Treatment Period I: Change From Baseline in Trunk Fat at Week 12 Changes in trunk fat was measured as changes in mass (kg) on Dual-Energy X-Ray Absorptiometry (DXA) Scan. Baseline, Week 12
Secondary Change From Baseline in Patient Reported Outcome of Body Image Distress at Week 12 Body image distress was assessed on a scale ranging from 0 to 100, where 0 = Extremely Upsetting and 100 = Extremely Encouraging. Baseline, Week 12
Secondary Treatment Period I: Change From Baseline in Non- High-density Lipoprotein (Non-HDL) Cholesterol at Week 12 Lipid profile data was analyzed for Non-HDL Cholesterol. Baseline, Week 12
Secondary Treatment Period II: Failure Rate at Week 36 Based on Visceral Adipose Tissue (VAT) For Subjects Who Received Serostim® 4 mg in Period I Failure rate based on VAT was assessed by CT scan at L4-L5. The failure rate was defined as the percentage of subjects who regained >50% of their VAT lost in Treatment Period I. This outcome was to be assessed for subjects who received Serostim® 4 mg in Period I. Week 36
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2